221 related articles for article (PubMed ID: 17026820)
1. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies.
Shivakumar L; Ansell S
Clin Lymphoma Myeloma; 2006 Sep; 7(2):106-8. PubMed ID: 17026820
[TBL] [Abstract][Full Text] [Related]
2. Human B lymphocyte malignancies: exploitation of BLyS and APRIL and their receptors.
Jelinek DF; Darce JR
Curr Dir Autoimmun; 2005; 8():266-88. PubMed ID: 15564725
[TBL] [Abstract][Full Text] [Related]
3. APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
Moreaux J; Sprynski AC; Dillon SR; Mahtouk K; Jourdan M; Ythier A; Moine P; Robert N; Jourdan E; Rossi JF; Klein B
Eur J Haematol; 2009 Aug; 83(2):119-29. PubMed ID: 19456850
[TBL] [Abstract][Full Text] [Related]
4. The uncertain glory of APRIL.
Medema JP; Planelles-Carazo L; Hardenberg G; Hahne M
Cell Death Differ; 2003 Oct; 10(10):1121-5. PubMed ID: 14502235
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.
Day ES; Cachero TG; Qian F; Sun Y; Wen D; Pelletier M; Hsu YM; Whitty A
Biochemistry; 2005 Feb; 44(6):1919-31. PubMed ID: 15697217
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus.
Morel J; Roubille C; Planelles L; Rocha C; Fernandez L; Lukas C; Hahne M; Combe B
Ann Rheum Dis; 2009 Jun; 68(6):997-1002. PubMed ID: 18676986
[TBL] [Abstract][Full Text] [Related]
7. APRIL and BAFF proteins increase proliferation of human adipose-derived stem cells through activation of Erk1/2 MAP kinase.
Zonca M; Mancheño-Corvo P; DelaRosa O; Mañes S; Büscher D; Lombardo E; Planelles L
Tissue Eng Part A; 2012 Apr; 18(7-8):852-9. PubMed ID: 22059379
[TBL] [Abstract][Full Text] [Related]
8. Targeting the BLyS-APRIL signaling pathway in SLE.
La Cava A
Clin Immunol; 2013 Sep; 148(3):322-7. PubMed ID: 23269199
[TBL] [Abstract][Full Text] [Related]
9. BLyS and B cell homeostasis.
Woodland RT; Schmidt MR; Thompson CB
Semin Immunol; 2006 Oct; 18(5):318-26. PubMed ID: 16931037
[TBL] [Abstract][Full Text] [Related]
10. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation.
Kim J; Gross JA; Dillon SR; Min JK; Elkon KB
Autoimmunity; 2011 Mar; 44(2):69-81. PubMed ID: 21250838
[TBL] [Abstract][Full Text] [Related]
11. The BAFF/APRIL system: life beyond B lymphocytes.
Ng LG; Mackay CR; Mackay F
Mol Immunol; 2005 May; 42(7):763-72. PubMed ID: 15829264
[TBL] [Abstract][Full Text] [Related]
12. APRIL is overexpressed in cancer: link with tumor progression.
Moreaux J; Veyrune JL; De Vos J; Klein B
BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
[TBL] [Abstract][Full Text] [Related]
13. The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.
Landau DA; Rosenzwajg M; Saadoun D; Klatzmann D; Cacoub P
Ann Rheum Dis; 2009 Mar; 68(3):337-44. PubMed ID: 18434450
[TBL] [Abstract][Full Text] [Related]
14. [Progress in the study of BLyS and APRIL on regulating T cell responses in rheumatoid arthritis].
Chang Y; Wei W
Yao Xue Xue Bao; 2013 Jul; 48(7):979-85. PubMed ID: 24133964
[TBL] [Abstract][Full Text] [Related]
15. Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development.
Alexaki VI; Notas G; Pelekanou V; Kampa M; Valkanou M; Theodoropoulos P; Stathopoulos EN; Tsapis A; Castanas E
J Immunol; 2009 Nov; 183(9):5948-56. PubMed ID: 19828625
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of BLyS/April in patients with acute idiopathic thrombocytopenic purpura].
Wang GB; Li CR; Li CG; Wang Y; Yang J
Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):595-8. PubMed ID: 19175985
[TBL] [Abstract][Full Text] [Related]
17. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils.
Scapini P; Bazzoni F; Cassatella MA
Immunol Lett; 2008 Feb; 116(1):1-6. PubMed ID: 18155301
[TBL] [Abstract][Full Text] [Related]
18. Identification of proteoglycans as the APRIL-specific binding partners.
Ingold K; Zumsteg A; Tardivel A; Huard B; Steiner QG; Cachero TG; Qiang F; Gorelik L; Kalled SL; Acha-Orbea H; Rennert PD; Tschopp J; Schneider P
J Exp Med; 2005 May; 201(9):1375-83. PubMed ID: 15851487
[TBL] [Abstract][Full Text] [Related]
19. Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.
Shi F; Xue R; Zhou X; Shen P; Wang S; Yang Y
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):666-673. PubMed ID: 34519594
[TBL] [Abstract][Full Text] [Related]
20. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
